Advertisement

Topics

Zylepsis Limited Company Profile

13:54 EDT 21st September 2017 | BioPortfolio

Our value is our unrivalled ability to enable almost limitless supplies of natural bioingredients to be produced with no harmful chemicals or genetic modification. To achieve this we have developed proprietary process technologies, including biotransformation and unique separation techniques, suitable for a wide range of applications. In essence, biotransformation uses natural microorganisms and enzymes to convert a starting material into a more useful and valuable compound. Zylepsis has built an extensive library of organisms (and enzymes) that work under mild conditions, usually in water, at non-extreme temperatures. They do not use toxic chemical reagents, nor do they leave harmful residues for disposal. In addition to these already considerable advantages, biotransformation often allows complex or unusual reactions to be performed, not possible using conventional chemistry. We are able to exploit the selectivity and specificity of enzymes and organisms to control the biocatalytic process that will produce the desired ingredient.

Location

6 Highpont, Henwood Business Estate
Ashford
Kent
TN24 8DH
United Kingdom

Contact

Phone: 01233 660 555
Fax: 01233 660 777
Email: info@zylepsis.co.uk


News Articles [14 Associated News Articles listed on BioPortfolio]

Quotient Limited to Participate in the UBS Global Healthcare Conference

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited

CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...

Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference

JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive O...

Quotient Limited to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

JERSEY, Channel Islands, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive...

Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix Pharmaceuticals Limited

MELBOURNE, Australia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have be...

Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and ...

Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results

Initial MosaiQ manufacturing system commissioned and validatedFirst “commercially ready” MosaiQ Instrument delivered to QuotientInternal validation of MosaiQ underway, with EU field trials expe...

Quotient Limited Reports Results From Latest MosaiQ Performance Evaluation Studies Prior to Commencing Verification and Validation Studies

Performance evaluation studies confirm required concordance levels for all assaysVerification and validation studies to commence shortly European field trials still expected to be completed in CY17...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [82 Associated Companies listed on BioPortfolio]

Zylepsis Limited

Our value is our unrivalled ability to enable almost limitless supplies of natural bioingredients to be produced with no harmful chemicals or genetic modification. To achieve this we have developed pr...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "Zylepsis Limited" on BioPortfolio

We have published hundreds of Zylepsis Limited news stories on BioPortfolio along with dozens of Zylepsis Limited Clinical Trials and PubMed Articles about Zylepsis Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Zylepsis Limited Companies in our database. You can also find out about relevant Zylepsis Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record